| __timestamp | AstraZeneca PLC | Summit Therapeutics Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 13324000000 | 6795238 |
| Thursday, January 1, 2015 | 11451000000 | 7454247 |
| Friday, January 1, 2016 | 9739000000 | 10345862 |
| Sunday, January 1, 2017 | 10543000000 | 16984203 |
| Monday, January 1, 2018 | 10362000000 | 16187290 |
| Tuesday, January 1, 2019 | 11848000000 | 9299233.54 |
| Wednesday, January 1, 2020 | 11693000000 | 19232000 |
| Friday, January 1, 2021 | 15680000000 | 23611000 |
| Saturday, January 1, 2022 | 18955000000 | 26700000 |
| Sunday, January 1, 2023 | 18025000000 | 28215000 |
| Monday, January 1, 2024 | 20532000000 |
Infusing magic into the data realm
In the competitive landscape of pharmaceuticals, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. AstraZeneca PLC, a global leader, and Summit Therapeutics Inc., a smaller biotech firm, present a fascinating contrast in SG&A spending from 2014 to 2023. Over this period, AstraZeneca's SG&A expenses have shown a steady increase, peaking at approximately $18 billion in 2022, reflecting a strategic expansion and investment in global operations. In contrast, Summit Therapeutics, with a more modest budget, saw its SG&A expenses grow from around $6.8 million in 2014 to nearly $28 million in 2023, indicating a significant scale-up in its operations. This comparison highlights the diverse strategies employed by large and small firms in managing operational costs while striving for market leadership.
Cost Management Insights: SG&A Expenses for Johnson & Johnson and AstraZeneca PLC
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Summit Therapeutics Inc.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and United Therapeutics Corporation
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Insmed Incorporated
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and Summit Therapeutics Inc.
Neurocrine Biosciences, Inc. and Summit Therapeutics Inc.: SG&A Spending Patterns Compared
Summit Therapeutics Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared